Across Global Alliance has partnered with Wemedoo AG to implement oomnia as its centralized clinical trial infrastructure, enhancing efficiency, compliance, and collaboration across its alliance membe ...

Q4 2024 net loss attributable to IEP of $98 million, an improvement of $41 million over Q4 2023; Q4 2024 quarter Adjusted EBI ...

US net sales, recognized by Viatris, reached an all-time high of $66.7 million in Q4 2024 and $238.6 million in FY 2024, up 10% and 8%, respectively ...

Vincerx Pharma, Inc. (Nasdaq: VINC) today announced that the previously signed binding Term Sheet between Vincerx, Oqory, Inc., and Vivasor, Inc.

Presented positive interim data through 52 weeks and beyond for 4D-150 in wet AMD from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patient populatio ...

Pivotal Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B (laromestrocel) in Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric disease and orphan-designated indication, has achieved more ...

Transaction included redemption of $1.0 billion 10.500% Senior Unsecured Notes MIAMI, Feb. 28, 2025 /PRNewswire/ -- Carnival Corporation & plc (NYSE/LSE: CCL; NYSE: ...

Toro Corp. (NASDAQ: TORO) ("Toro", or the "Company") an international energy transportation services company, announces that its Board of Directors ...

Saul Centers, Inc. (NYSE: BFS), an equity real estate investment trust ("REIT"), announced operating results for the ...

Mondelez International (Nasdaq: MDLZ) today announced the appointment of Norberto Chaclin as Executive Vice President and Chief Research & Development Officer.

Prior to completion of the transaction, Kinross held 5,100,000 Shares, representing approximately 6.8% of the issued and outstanding Shares, and 2,550,000 Share purchase warrants of Relevant Gold (the ...

Reference is made to the announcement by Kaldvik AS ("Kaldvik", the "Company") on 20 December 2024 regarding a potential acquisition of certain key assets in the fish ...